261P - Efficacy of chemotherapy in patients with unresectable or metastatic pancreatic acinar cell carcinoma: Potentially improved efficacy with oxaliplat...

Date 17 December 2016
Event ESMO Asia 2016 Congress
Session Poster lunch
Topics Anticancer Agents
Pancreatic Cancer
Presenter Jaekyung Cheon
Citation Annals of Oncology (2016) 27 (suppl_9): ix68-ix85. 10.1093/annonc/mdw582
Authors J. Cheon, C. Yoo, B. Kim, K. Kim, J. Lee, T.W. Kim, B. Ryoo, H. Chang
  • Medical Oncology, Asan Medical Center, University of Ulsan College of Medicine, 138-736 - Seoul/KR



Pancreatic acinar cell carcinoma (ACC) is a rare cancer of the exocrine pancreas. Because of its rare incidence, efficacy of chemotherapy in this patient population has been largely unknown. Therefore, we retrospectively analyzed the outcomes of patients with advanced pancreatic ACC who received chemotherapy.


Between January 1997 and March 2015, 15 patients with unresectable or metastatic pancreatic ACC who received systemic chemotherapy were identified in Asan Medical Center, Korea.


Median age was 58 years (range, 29–72 years). Eleven (73%) and 4 (27%) patients had recurrent/metastatic and locally advanced unresectable disease. Median overall survival in all patients was 20.9 months (95% CI, 15.7–26.1 months). As first-line therapy, intravenous 5-FU or oral fluoropyrimidine were administered in 6 patients (40%), gemcitabine in 5 (33%), gemcitabine plus capecitabine in 2 (13%), and FOLFOX in 2 (13%). Objective response rate (ORR) was 33% and median progression-free survival (PFS) was 5.8 months (95% CI, 3.1–8.4). After progression, second-line chemotherapy was administered in 8 patients; 4 patients received FOLFOX and the other 4 patients received gemcitabine. ORR was 38%, and patients administered FOLFOX had significantly better PFS than those administered gemcitabine (median 6.5 vs. 1.4 months, p = 0.007). The ratio of Time to tumor progression (TTP) at first-line chemotherapy to TTP at second-line chemotherapy was significantly higher in patients administered FOLFOX (4.07 [range, 0.87–8.30]) than in those administered gemcitabine (0.12 [0.08–0.25]; p = 0.029).


Our results suggest that oxaliplatin-containing regimens may have improved activity against pancreatic ACC.

Clinical trial indentification

Legal entity responsible for the study

Jaekyung Cheon, Asan Medical Center




All authors have declared no conflicts of interest.